Contribution of the R-Ras2 GTP-binding protein to primary breast tumorigenesis and late-stage metastatic disease

Nature Communications

Volumn 5, Issue , 2014, Pages

  Larive, Romain M ^a   Moriggi, Giulia ^b   Menacho Márquez, Mauricio ^c   Cañamero, Marta ^d   Álava, Enrique De ^e   Alarcón, Balbino ^f   Dosil, Mercedes ^g   Bustelo, Xosé R ^a  

^a CSIC   (Spain)

^b Salamanca Spain   (Spain)

^c Structural Biology and Biocomputing Programme   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^f UNIVERSITY OF SALAMANCA   (Spain)

^g Centre National de la Recherche Scientifique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GUANINE NUCLEOTIDE BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; R RAS 2 GUANINE NUCLEOTIDE BINDING PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; RRAS2 PROTEIN, HUMAN; RRAS2 PROTEIN, MOUSE;

CANCER; DISEASE TREATMENT; PROTEIN; RODENT; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER CELL; CARCINOGENIC ACTIVITY; CARCINOGENICITY; CELL SURVIVAL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LUNG PARENCHYMA; MAMMARY GLAND; METASTASIS; METASTASIS POTENTIAL; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PROTEIN SYNTHESIS REGULATION; SIGNAL TRANSDUCTION; UPREGULATION; ADENOCARCINOMA; ANIMAL; BREAST TUMOR; CARCINOGENESIS; CELL LINE; DISEASE MODEL; GENETICS; LUNG TUMOR; PATHOLOGY; SECONDARY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CARCINOGENESIS; CELL LINE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE; MONOMERIC GTP-BINDING PROTEINS; NEOPLASM METASTASIS;

EID: 84900846735     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4881     Document Type: Article

References (52)

1. Rojas, A. M., Fuentes, G., Rausell, A. &Valencia, A. The Ras protein superfamily: evolutionary tree and role of conserved amino acids. J. Cell Biol. 196, 189-201 (2012).
2. Chan, A. M., Miki, T., Meyers, K. A. &Aaronson, S. A. A human oncogene of the RAS superfamily unmasked by expression cDNA cloning. Proc. Natl Acad. Sci. USA 91, 7558-7562 (1994). (Pubitemid 24238224)
3. Graham, S. M. et al. Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation. Mol. Cell Biol. 14, 4108-4115 (1994). (Pubitemid 24160816)
4. Graham, S. M. et al. TC21 and Ras share indistinguishable transforming and differentiating activities. Oncogene 18, 2107-2116 (1999). (Pubitemid 29178579)
5. Movilla, N., Crespo, P. &Bustelo, X. R. Signal transduction elements of TC21, an oncogenic member of the R-Ras subfamily of GTP-binding proteins. Oncogene 18, 5860-5869 (1999).
6. Rosario, M., Paterson, H. F. &Marshall, C. J. Activation of the Raf/MAP kinase cascade by the Ras-related protein TC21 is required for the TC21-mediated transformation of NIH 3T3 cells. EMBO J. 18, 1270-1279 (1999). (Pubitemid 29110311)
7. Rosario, M., Paterson, H. F. &Marshall, C. J. Activation of the Ral and phosphatidylinositol 30 kinase signaling pathways by the ras-related protein TC21. Mol. Cell Biol. 21, 3750-3762 (2001). (Pubitemid 32466988)
8. McFall, A. et al. Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase. Mol. Cell Biol. 21, 5488-5499 (2001). (Pubitemid 32702453)
9. Murphy, G. A. et al. Involvement of phosphatidylinositol 3-kinase, but not RalGDS, in TC21/R-Ras2-mediated transformation. J. Biol. Chem. 277, 9966-9975 (2002). (Pubitemid 34968104)
10. Rong, R., He, Q., Liu, Y., Sheikh, M. S. &Huang, Y. TC21 mediates transformation and cell survival via activation of phosphatidylinositol 3-kinase/Akt and NF-kappaB signaling pathway. Oncogene 21, 1062-1070 (2002). (Pubitemid 34174518)
11. Lopez-Barahona, M., Bustelo, X. R. &Barbacid, M. The TC21 oncoprotein interacts with the Ral guanosine nucleotide dissociation factor. Oncogene 12, 463-470 (1996). (Pubitemid 26059639)
12. Graham, S. M. et al. TC21 causes transformation by Raf-independent signaling pathways. Mol. Cell Biol. 16, 6132-6140 (1996). (Pubitemid 26360973)
13. Light, Y., Paterson, H. &Marais, R. 14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity. Mol. Cell Biol. 22, 4984-4996 (2002). (Pubitemid 34700691)
14. Barker, K. T. &Crompton, M. R. Ras-related TC21 is activated by mutation in a breast cancer cell line, but infrequently in breast carcinomas in vivo. Br. J. Cancer 78, 296-300 (1998). (Pubitemid 28336414)
15. Clark, G. J., Kinch, M. S., Gilmer, T. M., Burridge, K. &Der, C. J. Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene 12, 169-176 (1996). (Pubitemid 26041253)
16. Erdogan, M., Pozzi, A., Bhowmick, N., Moses, H. L. &Zent, R. Signaling pathways regulating TC21-induced tumorigenesis. J. Biol. Chem. 282, 27713-27720 (2007). (Pubitemid 47529543)
17. Erdogan, M., Pozzi, A., Bhowmick, N., Moses, H. L. &Zent, R. Transforming growth factor-beta (TGF-beta) and TGF-beta-associated kinase 1 are required for R-Ras-mediated transformation of mammary epithelial cells. Cancer Res. 68, 6224-6231 (2008).
18. Larive, R. M. et al. The Ras-like protein R-Ras2/TC21 is important for proper mammary gland development. Mol. Biol. Cell 23, 2373-2387 (2012).
19. Mendes-Pereira, A. M. et al. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc. Natl Acad. Sci. USA 109, 2730-2735 (2011).
20. Rokavec, M. et al. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer. Cancer Res. 68, 9799-9808 (2008).
21. Patmore, D. M. et al. In vivo regulation of TGF-beta by R-Ras2 revealed through loss of the RasGAP protein NF1. Cancer Res. 72, 5317-5327 (2012).
22. Hollestelle, A., Elstrodt, F., Nagel, J. H., Kallemeijn, W. W. &Schutte, M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol. Cancer Res. 5, 195-201 (2007). (Pubitemid 46424000)
23. Weigelt, B., Warne, P. H. &Downward, J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30, 3222-3233 (2011).
24. Dey, J. H. et al. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res. 70, 4151-4162 (2010).
25. Aslakson, C. J. &Miller, F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399-1405 (1992).
26. Bustelo, X. R. Intratumoral stages of metastatic cells: a synthesis of ontogeny, Rho/Rac GTPases, epithelial-mesenchymal transitions, and more. Bioessays 34, 748-759 (2012).
27. Nguyen, D. X., Bos, P. D. &Massague, J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274-284 (2009).
28. Wennstrom, S. &Downward, J. Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol. Cell Biol. 19, 4279-4288 (1999). (Pubitemid 29242003)
29. Fluck, M. M. &Schaffhausen, B. S. Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol. Mol. Biol. Rev. 73, 542-563 (2009).
30. Utermark, T. et al. The p110alpha and p110beta isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 26, 1573-1586 (2012).
31. Ju, X. et al. Akt1 governs breast cancer progression in vivo. Proc. Natl Acad. Sci. 104, 7438-7443 (2007). (Pubitemid 47185924)
32. Gjorevski, N. &Nelson, C. M. Integrated morphodynamic signalling of the mammary gland. Nat. Rev. Mol. Cell Biol. 12, 581-593 (2011).
33. Castellano, E. &Downward, J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2, 261-274 (2011).
34. Navas, C. et al. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22, 318-330 (2012).
35. Toulany, M., Baumann, M. &Rodemann, H. P. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol. Cancer Res. 5, 863-872 (2007). (Pubitemid 47294813)
36. Prober, D. A. &Edgar, B. A. Interactions between Ras1, dMyc, and dPI3K signaling in the developing Drosophila wing. Genes Dev. 16, 2286-2299 (2002). (Pubitemid 35013091)
37. Ebi, H. et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J. Clin. Invest. 121, 4311-4321 (2011).
38. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. &Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329-341 (2010).
39. Chan, S. et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23, 5314-5322 (2005). (Pubitemid 46206985)
40. Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065-3074 (2008).
41. Ellard, S. L. et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J. Clin. Oncol. 27, 4536-4541 (2009).
42. Baselga, J. et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 27, 2630-2637 (2009).
43. Serra, V. et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30, 2547-2557 (2011).
44. Aksamitiene, E., Kholodenko, B. N., Kolch, W., Hoek, J. B. &Kiyatkin, A. PI3K/ Akt-sensitive MEK-independent compensatory circuit of ERK activation in ERpositive PI3K-mutant T47D breast cancer cells. Cell Signal. 22, 1369-1378 (2010).
45. Liu, P. et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat. Med. 17, 1116-1120 (2011).
46. Gupta, G. P. &Massague, J. Cancer metastasis: building a framework. Cell 127, 679-695 (2006). (Pubitemid 44781029)
47. Ilic, N., Utermark, T., Widlund, H. R. &Roberts, T. M. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl Acad. Sci. USA 108, E699-E708 (2011).
48. Jackson, S. P. et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat. Med. 11, 507-514 (2005). (Pubitemid 40685973)
49. Knight, Z. A. et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125, 733-747 (2006).
50. Delgado, P. et al. Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nat. Immunol. 10, 880-888 (2009).
51. Citterio, C. et al. The Rho exchange factors Vav2 and Vav3 control a lung metastasis-specific transcriptional program in breast cancer cells. Sci Signal. 5, ra71 (2012).
52. Dosil, M. &Bustelo, X. R. Functional characterization of Pwp2, a WD family protein essential for the assembly of the 90 S pre-ribosomal particle. J. Biol. Chem. 279, 37385-37397 (2004). (Pubitemid 39195447)